Clarus Therapeutics Holdings Inc (CRXT) Stock
CRXT is no longer traded. Clarus Therapeutics Holdings was delisted from the Nasdaq in November 2022.
Prices on this page are historical; the last trade was November 8, 2022 at $0.02.
Clarus Therapeutics Holdings stock price history
CRXT final trading statistics
- Final close
- $0.02
- Final trading day
- Nov 8, 2022
- Market cap at delisting
- $2.47M
- Shares outstanding
- 52.02M
- Final 52-week range
- $0.01 – $7.14
- Avg. volume (final 3 mo.)
- 1,613,632
- All-time high (split-adj.)
- $10.45 · Aug 2021
- All-time low (split-adj.)
- $0.02 · Oct 2022
- Return since IPO
- -99.8%
- Beta
- —
- Book value / share
- —
- Price / book
- —
Clarus Therapeutics Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $13.96M | -$40.6M | -$3.08 |
| FY2020 | $6.37M | $4.3M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Clarus Therapeutics Holdings Inc
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Clarus Therapeutics Holdings stock FAQ
What happened to Clarus Therapeutics Holdings stock?
Clarus Therapeutics Holdings stock was delisted from the Nasdaq. Its final close was $0.02 on November 8, 2022.
Is CRXT stock still trading?
No. CRXT was delisted from the Nasdaq in November 2022 and no longer trades on a U.S. exchange.
What was the last price of CRXT stock?
CRXT closed at $0.02 on its final trading day, November 8, 2022, for a market value of about $2.47M.
What were Clarus Therapeutics Holdings's revenue and earnings in its last full fiscal year?
Clarus Therapeutics Holdings reported revenue of $13.96M and net income of -$40.6M in fiscal 2021, its last full year as a public company.
When did Clarus Therapeutics Holdings go public?
Clarus Therapeutics Holdings Inc stock began trading on September 9, 2021.